Cellyan Biotechnology Co., Ltd. filings document the foreign private issuer’s OTC pharmaceutical cross-border e-commerce supply chain operations, public-company governance, and capital structure. Form 6-K reports include interim consolidated financial statements, operating and financial review materials, and disclosures related to the company’s Class A ordinary shares.
The filing record also covers annual general meeting materials, board and officer changes, independent director appointments, amended constitutional documents, an equity incentive plan, share repurchase and Class B ordinary share matters, Nasdaq minimum bid-price compliance notices, and financing arrangements involving units, warrants, and resale registration rights.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reported that it will hold its annual general meeting of shareholders on December 12, 2025 at 10:00 a.m. Hong Kong Time (December 11, 2025 at 9:00 p.m. Eastern Time). The meeting will take place at the company’s principal office in Yau Tong, Kowloon, Hong Kong.
The company is providing shareholders with a proxy statement and notice of meeting, a form of proxy card, a proposed 2025 Equity Incentive Plan, and a form of fourth amended and restated memorandum and articles of association, all of which are furnished as exhibits and incorporated by reference.
Hong Kong Pharma Digital Technology Holdings Limited reported major leadership changes. On October 6, 2025, the board accepted the immediate resignations of its Chief Executive Officer, Executive Director, and Chief Financial Officer, all citing personal reasons and no disagreements with the company or board. Earlier, on April 30, 2025, the Chief Operating Officer also resigned for personal reasons.
The board simultaneously rebuilt the senior team by appointing Chenyu Liang as Director and Chief Executive Officer, Shu Liu as Chief Financial Officer, and Zifeng Wang as Chief Strategy Officer, each with prior management and industry experience. They entered employment agreements providing annual base salaries of HKD100,000 for Mr. Liang and Ms. Liu and HKD70,000 for Mr. Wang.
Hong Kong Pharma Digital Technology Holdings Limited reported that its board appointed Mr. Zhou Mike Yao as an independent director effective September 9, 2025, and named him to the board’s nomination committee. Mr. Zhou, aged 34, has experience in investment, capital markets and corporate development, including roles at Norwich Capital Limited, MYZ Corporate Relations Ltd., Direct Communication Solutions Inc. and Explorex Resource Inc. The board determined he meets the Nasdaq definition of an independent director.
The company will pay Mr. Zhou annual compensation of HK$100,000, payable quarterly in arrears, and has entered into its standard indemnification agreement for directors to protect him in connection with his board service. The board notes that there are no related party transactions requiring disclosure and states its belief that Mr. Zhou will bring broad management experience to the company.
Hong Kong Pharma Digital Technology Holdings Limited (HKPD) reports fiscal results and an extensive risk disclosure in its Form 20-F. The company completed a 1-for-10 share subdivision that increased issued shares to 11,000,000 (11,000 par units reported) and completed an IPO. Consolidated revenue lines shown in the filing include totals such as $20,313,818 and operating segments with revenue amounts like $7,511,591 and $6,217,798. The company recorded a net profit of $1,329,717 for one reported year and basic earnings per share of $0.180. Major shareholders and insider holdings are disclosed: the group of directors and officers hold 56.77% beneficially; Lap Sun Wong is identified as CEO and Chairman and retains controlling voting power. The filing lists extensive regulatory, geopolitical and operational risks, including concentration of customers and suppliers, IT and data governance risks, potential impact of PRC/Hong Kong regulation, possible Nasdaq listing pressures (past share price under $1 and delisting risk), and dependence on HK subsidiaries for cash distributions. The report also discloses material leases, licenses, and bank borrowings and notes key operating costs such as transportation and storage.